P5333Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis) — Michael Mæng (2018) | RDL Network
P5333Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis)
Michael Mæng, Philippe Gabríel Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Takeshi Kimura, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Laura Mauri, P S Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Takeshi Kimura, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Philippe Gabríel Steg, Grégory Ducrocq, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Christopher P. Cannon, Deepak L. Bhatt, Jonas Oldgren, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Michael Mæng, Béla Merkely, Uwe Zeymer, Savion Gropper, Matias Nordaby, Eva Kleine, Ruth Harper, Jenny Manassie, James L. Januzzi, Jurriën M. ten Berg, Philippe Gabríel Steg, Stefan H. Hohnloser
Jonas Oldgren, Philippe Gabríel Steg, Stefan H. Hohnloser, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Matias Nordaby, Jurriën M. ten Berg, Deepak L. Bhatt, Christopher P. Cannon, Eva Kleine
Discussion(0)
No comments yet. Be the first to comment.